Hydroxynorketamine

Hydroxynorketamine (HNK) refers to a family of twelve stereoisomeric metabolites of the dissociative anesthetic and rapid-acting antidepressant ketamine, formed by cytochrome P450-mediated hydroxylation of the intermediate metabolite norketamine at the 4-, 5-, or 6-position of the cyclohexane ring. The (2R,6R)-hydroxynorketamine stereoisomer ((2R,6R)-HNK) has emerged as the compound of greatest pharmacological interest following the seminal 2016 report by Zanos et al. in Nature demonstrating that this metabolite is both necessary and sufficient for the antidepressant actions of ketamine in rodent models, while lacking the anesthetic, dissociative, psychotomimetic, and abuse-related properties of the parent compound. The molecular pharmacology of (2R,6R)-HNK is distinct from ketamine: at concentrations relevant to antidepressant activity, (2R,6R)-HNK does not produce meaningful inhibition of N-methyl-D-aspartate (NMDA) receptors, but instead potentiates alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated glutamatergic transmission through a presynaptic mechanism that increases glutamate release probability and enhances synaptic plasticity in hippocampal and prefrontal cortical circuits. Downstream consequences include activity-dependent release of brain-derived neurotrophic factor (BDNF), activation of tropomyosin receptor kinase B (TrkB) signaling, stimulation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway, and rapid synaptogenesis in the medial prefrontal cortex. Additional mechanistic contributions involve metabotropic glutamate receptor subtype 2 (mGlu2) receptor-dependent signaling and antagonism of alpha-7 nicotinic acetylcholine receptors controlling presynaptic function and neuroplasticity gene expression. Pharmacokinetically, (2R,6R)-HNK is formed in vivo from (R)-ketamine through sequential N-demethylation (predominantly CYP2B6 and CYP3A4) to (R)-norketamine and subsequent 6-hydroxylation (predominantly CYP2B6 and CYP2A6). The metabolite is brain-penetrant following peripheral administration, with rapid onset of central nervous system exposure. A Phase 1 clinical trial (NCT04711005) published by Raja et al. in 2024 demonstrated excellent safety and tolerability of intravenous (2R,6R)-HNK at doses from 0.1 to 4 mg/kg in healthy volunteers, with no dissociative effects, no serious adverse events, and a pharmacokinetic profile consistent with once-daily or intermittent dosing. Phase 2 trials in treatment-resistant depression (NCT06511908) and Phase 1/2 trials in neuropathic pain (NCT05864053) and obsessive-compulsive disorder (NCT06575075) are currently enrolling. Preclinical evidence across multiple rodent models demonstrates antidepressant-like, anxiolytic, analgesic, and anti-inflammatory effects, with effect sizes comparable to or exceeding those of the parent ketamine in several paradigms and duration of action extending well beyond the plasma residence time, consistent with a synaptic plasticity-dependent rather than receptor occupancy-dependent mechanism. This monograph reviews the chemistry, stereochemistry, and metabolic origin of hydroxynorketamine; the molecular pharmacology at AMPA, NMDA, mGlu2, alpha-7 nicotinic, and opioid receptors; the comprehensive pharmacokinetic record; the preclinical evidence base across depression, pain, anxiety, and substance use disorder models; the emerging clinical evidence from Phase 1 and ongoing Phase 2 trials; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five rapid-acting antidepressant candidates against hydroxynorketamine on five competency standards.